Annual CFF
$30.00 K
-$1.48 M-98.01%
31 December 2023
Summary:
Nektar Therapeutics annual cash flow from financing activities is currently $30.00 thousand, with the most recent change of -$1.48 million (-98.01%) on 31 December 2023. During the last 3 years, it has risen by +$80.38 million (+100.04%). NKTR annual CFF is now -100.00% below its all-time high of $851.97 million, reached on 31 December 2018.NKTR Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$13.00 K
-$6000.00-31.58%
30 September 2024
Summary:
Nektar Therapeutics quarterly cash flow from financing activities is currently $13.00 thousand, with the most recent change of -$6000.00 (-31.58%) on 30 September 2024. Over the past year, it has increased by +$13.00 thousand (+100.00%). NKTR quarterly CFF is now -100.00% below its all-time high of $811.09 million, reached on 30 June 2018.NKTR Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$42.05 M
+$13.00 K+0.03%
30 September 2024
Summary:
Nektar Therapeutics TTM cash flow from financing activities is currently $42.05 million, with the most recent change of +$13.00 thousand (+0.03%) on 30 September 2024. Over the past year, it has increased by +$41.93 million (+34649.59%). NKTR TTM CFF is now -95.22% below its all-time high of $879.18 million, reached on 30 June 2018.NKTR TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NKTR Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -98.0% | +100.0% | +10000.0% |
| 3 y3 years | +100.0% | -99.7% | -77.0% |
| 5 y5 years | -100.0% | -99.8% | +99.1% |
NKTR Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -99.9% | +100.0% | -100.0% | -77.0% | >+9999.0% | |
| 5 y | 5 years | -100.0% | +100.0% | -100.0% | +100.0% | -77.0% | +118.7% |
| alltime | all time | -100.0% | +100.0% | -100.0% | +100.0% | -95.2% | +118.7% |
Nektar Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $13.00 K(-31.6%) | $42.05 M(+0.0%) |
| June 2024 | - | $19.00 K(-100.0%) | $42.03 M(+0.0%) |
| Mar 2024 | - | $42.00 M(>+9900.0%) | $42.03 M(>+9900.0%) |
| Dec 2023 | $30.00 K(-98.0%) | $12.00 K(>+9900.0%) | $30.00 K(-75.2%) |
| Sept 2023 | - | $0.00(-100.0%) | $121.00 K(0.0%) |
| June 2023 | - | $18.00 K(>+9900.0%) | $121.00 K(-78.8%) |
| Mar 2023 | - | $0.00(-100.0%) | $570.00 K(-62.2%) |
| Dec 2022 | $1.51 M(-95.8%) | $103.00 K(>+9900.0%) | $1.51 M(-61.9%) |
| Sept 2022 | - | $0.00(-100.0%) | $3.96 M(-48.1%) |
| June 2022 | - | $467.00 K(-50.2%) | $7.62 M(-60.6%) |
| Mar 2022 | - | $938.00 K(-63.2%) | $19.32 M(-46.7%) |
| Dec 2021 | $36.24 M(-145.1%) | $2.55 M(-30.3%) | $36.24 M(-80.2%) |
| Sept 2021 | - | $3.66 M(-69.9%) | $182.68 M(+1.2%) |
| June 2021 | - | $12.17 M(-31.9%) | $180.55 M(-345.4%) |
| Mar 2021 | - | $17.86 M(-88.0%) | -$73.58 M(-8.4%) |
| Dec 2020 | -$80.35 M(-444.1%) | $149.00 M(+9631.9%) | -$80.35 M(-64.2%) |
| Sept 2020 | - | $1.53 M(-100.6%) | -$224.44 M(+2.1%) |
| June 2020 | - | -$241.96 M(-2284.3%) | -$219.72 M(-843.9%) |
| Mar 2020 | - | $11.08 M(+125.8%) | $29.54 M(+26.5%) |
| Dec 2019 | $23.36 M(-97.3%) | $4.91 M(-21.5%) | $23.36 M(+10.6%) |
| Sept 2019 | - | $6.25 M(-14.5%) | $21.12 M(+12.8%) |
| June 2019 | - | $7.31 M(+49.3%) | $18.73 M(-97.7%) |
| Mar 2019 | - | $4.89 M(+83.4%) | $822.51 M(-3.5%) |
| Dec 2018 | $851.97 M(+1466.4%) | $2.67 M(-30.9%) | $851.97 M(-2.5%) |
| Sept 2018 | - | $3.86 M(-99.5%) | $873.57 M(-0.6%) |
| June 2018 | - | $811.09 M(+2261.1%) | $879.18 M(+1033.5%) |
| Mar 2018 | - | $34.35 M(+41.5%) | $77.56 M(+42.6%) |
| Dec 2017 | $54.39 M(-73.3%) | $24.27 M(+156.4%) | $54.39 M(-75.4%) |
| Sept 2017 | - | $9.47 M(+0.0%) | $221.07 M(+1.3%) |
| June 2017 | - | $9.47 M(-15.3%) | $218.14 M(+3.7%) |
| Mar 2017 | - | $11.18 M(-94.1%) | $210.42 M(+3.3%) |
| Dec 2016 | $203.62 M(+55.7%) | $190.95 M(+2820.2%) | $203.62 M(+54.6%) |
| Sept 2016 | - | $6.54 M(+273.0%) | $131.73 M(+0.1%) |
| June 2016 | - | $1.75 M(-59.9%) | $131.59 M(-2.2%) |
| Mar 2016 | - | $4.37 M(-96.3%) | $134.57 M(+2.9%) |
| Dec 2015 | $130.78 M(-14.5%) | $119.06 M(+1759.2%) | $130.78 M(+214.6%) |
| Sept 2015 | - | $6.40 M(+35.5%) | $41.58 M(-1.9%) |
| June 2015 | - | $4.73 M(+705.3%) | $42.39 M(+6.8%) |
| Mar 2015 | - | $587.00 K(-98.0%) | $39.70 M(-74.0%) |
| Dec 2014 | $152.98 M(+6803.6%) | $29.86 M(+313.9%) | $152.98 M(+22.1%) |
| Sept 2014 | - | $7.21 M(+252.9%) | $125.29 M(+4.4%) |
| June 2014 | - | $2.04 M(-98.2%) | $119.97 M(+1.2%) |
| Mar 2014 | - | $113.87 M(+5161.9%) | $118.56 M(+5250.1%) |
| Dec 2013 | $2.22 M(-91.7%) | $2.16 M(+14.1%) | $2.22 M(+745.8%) |
| Sept 2013 | - | $1.90 M(+201.6%) | $262.00 K(-100.3%) |
| June 2013 | - | $629.00 K(-125.4%) | -$94.82 M(-0.4%) |
| Mar 2013 | - | -$2.47 M(-1278.1%) | -$95.17 M(-455.1%) |
| Dec 2012 | $26.80 M(-87.9%) | $210.00 K(-100.2%) | $26.80 M(+2.0%) |
| Sept 2012 | - | -$93.18 M(<-9900.0%) | $26.29 M(-78.0%) |
| June 2012 | - | $273.00 K(-99.8%) | $119.50 M(-0.7%) |
| Mar 2012 | - | $119.50 M(<-9900.0%) | $120.34 M(-45.9%) |
| Dec 2011 | $222.34 M(+2850.7%) | -$306.00 K(-1276.9%) | $222.34 M(-0.8%) |
| Sept 2011 | - | $26.00 K(-97.7%) | $224.15 M(-0.3%) |
| June 2011 | - | $1.12 M(-99.5%) | $224.73 M(+0.1%) |
| Mar 2011 | - | $221.50 M(>+9900.0%) | $224.62 M(+2881.0%) |
| Dec 2010 | $7.54 M(+113.2%) | $1.51 M(+149.5%) | $7.54 M(+12.9%) |
| Sept 2010 | - | $606.00 K(-39.4%) | $6.67 M(-29.6%) |
| June 2010 | - | $1.00 M(-77.4%) | $9.48 M(+15.7%) |
| Mar 2010 | - | $4.42 M(+580.6%) | $8.19 M(+131.8%) |
| Dec 2009 | $3.54 M | $649.00 K(-81.0%) | $3.54 M(-107.8%) |
| Sept 2009 | - | $3.41 M(-1297.2%) | -$45.42 M(-8.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | -$285.00 K(+18.3%) | -$49.50 M(-0.9%) |
| Mar 2009 | - | -$241.00 K(-99.5%) | -$49.94 M(+0.4%) |
| Dec 2008 | -$49.74 M(-51.1%) | -$48.31 M(+7164.4%) | -$49.74 M(-28.8%) |
| Sept 2008 | - | -$665.00 K(-8.7%) | -$69.87 M(+2.2%) |
| June 2008 | - | -$728.00 K(+1720.0%) | -$68.39 M(+1.3%) |
| Mar 2008 | - | -$40.00 K(-99.9%) | -$67.52 M(-33.7%) |
| Dec 2007 | -$101.77 M(-964.6%) | -$68.43 M(-8580.0%) | -$101.77 M(+294.4%) |
| Sept 2007 | - | $807.00 K(+434.4%) | -$25.80 M(-12.1%) |
| June 2007 | - | $151.00 K(-100.4%) | -$29.37 M(+5.0%) |
| Mar 2007 | - | -$34.29 M(-555.4%) | -$27.97 M(-337.6%) |
| Dec 2006 | $11.77 M(-95.7%) | $7.53 M(-372.7%) | $11.77 M(+173.7%) |
| Sept 2006 | - | -$2.76 M(-277.6%) | $4.30 M(-98.4%) |
| June 2006 | - | $1.55 M(-71.5%) | $277.30 M(-0.3%) |
| Mar 2006 | - | $5.45 M(+9132.2%) | $278.15 M(+1.2%) |
| Dec 2005 | $274.85 M(+32.5%) | $59.00 K(-100.0%) | $274.85 M(-2.5%) |
| Sept 2005 | - | $270.24 M(>+9900.0%) | $281.84 M(+2931.8%) |
| June 2005 | - | $2.40 M(+11.9%) | $9.30 M(+11.4%) |
| Mar 2005 | - | $2.15 M(-69.5%) | $8.35 M(-96.0%) |
| Dec 2004 | $207.41 M(+104.8%) | $7.05 M(-405.9%) | $207.41 M(+0.5%) |
| Sept 2004 | - | -$2.30 M(-258.2%) | $206.32 M(-7.1%) |
| June 2004 | - | $1.46 M(-99.3%) | $222.17 M(-26.6%) |
| Mar 2004 | - | $201.22 M(+3281.8%) | $302.56 M(+198.7%) |
| Dec 2003 | $101.30 M(+161.6%) | $5.95 M(-56.1%) | $101.30 M(+8.3%) |
| Sept 2003 | - | $13.55 M(-83.4%) | $93.56 M(+16.5%) |
| June 2003 | - | $81.84 M(<-9900.0%) | $80.34 M(-6313.1%) |
| Mar 2003 | - | -$42.00 K(-97.6%) | -$1.29 M(-103.3%) |
| Dec 2002 | $38.72 M(+71.2%) | -$1.78 M(-656.1%) | $38.72 M(-11.0%) |
| Sept 2002 | - | $321.00 K(+50.7%) | $43.50 M(-7.7%) |
| June 2002 | - | $213.00 K(-99.5%) | $47.14 M(-16.2%) |
| Mar 2002 | - | $39.98 M(+1236.1%) | $56.24 M(+148.7%) |
| Dec 2001 | $22.61 M(-94.8%) | $2.99 M(-24.5%) | $22.61 M(-90.5%) |
| Sept 2001 | - | $3.96 M(-57.4%) | $239.11 M(+0.4%) |
| June 2001 | - | $9.31 M(+46.5%) | $238.09 M(+3.0%) |
| Mar 2001 | - | $6.35 M(-97.1%) | $231.19 M(-47.2%) |
| Dec 2000 | $438.07 M(+312.2%) | $219.49 M(+7365.6%) | $438.07 M(+35.4%) |
| Sept 2000 | - | $2.94 M(+22.1%) | $323.57 M(+0.6%) |
| June 2000 | - | $2.41 M(-98.9%) | $321.63 M(+0.7%) |
| Mar 2000 | - | $213.23 M(+103.1%) | $319.47 M(+200.6%) |
| Dec 1999 | $106.29 M(+190.9%) | $104.99 M(>+9900.0%) | $106.29 M(+189.3%) |
| Sept 1999 | - | $1.00 M(+308.2%) | $36.73 M(+3.0%) |
| June 1999 | - | $245.00 K(+345.5%) | $35.68 M(-0.8%) |
| Mar 1999 | - | $55.00 K(-99.8%) | $35.96 M(-1.6%) |
| Dec 1998 | $36.53 M(-52.0%) | $35.44 M(<-9900.0%) | $36.53 M(-20.0%) |
| Sept 1998 | - | -$54.00 K(-110.3%) | $45.65 M(-2.4%) |
| June 1998 | - | $523.00 K(-17.1%) | $46.77 M(+1.2%) |
| Mar 1998 | - | $631.00 K(-98.6%) | $46.23 M(-39.3%) |
| Dec 1997 | $76.11 M(+211.9%) | $44.55 M(+4095.2%) | $76.11 M(+108.2%) |
| Sept 1997 | - | $1.06 M(-8269.2%) | $36.56 M(+3.0%) |
| June 1997 | - | -$13.00 K(-100.0%) | $35.50 M(-35.5%) |
| Mar 1997 | - | $30.51 M(+510.2%) | $55.01 M(+125.5%) |
| Dec 1996 | $24.40 M(+100.0%) | $5.00 M(>+9900.0%) | $24.40 M(+25.1%) |
| Sept 1996 | - | $0.00(-100.0%) | $19.50 M(0.0%) |
| June 1996 | - | $19.50 M(<-9900.0%) | $19.50 M(<-9900.0%) |
| Mar 1996 | - | -$100.00 K(-200.0%) | -$100.00 K(-100.8%) |
| Dec 1995 | $12.20 M(-14.7%) | $100.00 K(>+9900.0%) | $12.20 M(+0.8%) |
| Sept 1995 | - | $0.00(-100.0%) | $12.10 M(+1.7%) |
| June 1995 | - | -$100.00 K(-100.8%) | $11.90 M(-55.3%) |
| Mar 1995 | - | $12.20 M(>+9900.0%) | $26.60 M(+86.0%) |
| Dec 1994 | $14.30 M | $0.00(-100.0%) | $14.30 M(0.0%) |
| Sept 1994 | - | -$200.00 K(-101.4%) | $14.30 M(-1.4%) |
| June 1994 | - | $14.60 M(<-9900.0%) | $14.50 M(<-9900.0%) |
| Mar 1994 | - | -$100.00 K | -$100.00 K |
FAQ
- What is Nektar Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Nektar Therapeutics?
- What is Nektar Therapeutics annual CFF year-on-year change?
- What is Nektar Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Nektar Therapeutics?
- What is Nektar Therapeutics quarterly CFF year-on-year change?
- What is Nektar Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Nektar Therapeutics?
- What is Nektar Therapeutics TTM CFF year-on-year change?
What is Nektar Therapeutics annual cash flow from financing activities?
The current annual CFF of NKTR is $30.00 K
What is the all time high annual CFF for Nektar Therapeutics?
Nektar Therapeutics all-time high annual cash flow from financing activities is $851.97 M
What is Nektar Therapeutics annual CFF year-on-year change?
Over the past year, NKTR annual cash flow from financing activities has changed by -$1.48 M (-98.01%)
What is Nektar Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of NKTR is $13.00 K
What is the all time high quarterly CFF for Nektar Therapeutics?
Nektar Therapeutics all-time high quarterly cash flow from financing activities is $811.09 M
What is Nektar Therapeutics quarterly CFF year-on-year change?
Over the past year, NKTR quarterly cash flow from financing activities has changed by +$13.00 K (+100.00%)
What is Nektar Therapeutics TTM cash flow from financing activities?
The current TTM CFF of NKTR is $42.05 M
What is the all time high TTM CFF for Nektar Therapeutics?
Nektar Therapeutics all-time high TTM cash flow from financing activities is $879.18 M
What is Nektar Therapeutics TTM CFF year-on-year change?
Over the past year, NKTR TTM cash flow from financing activities has changed by +$41.93 M (+34649.59%)